AstraZeneca's Strong First Quarter Includes Significant Emerging Markets Growth
This article was originally published in PharmAsia News
Having endured one major patent expiry in the past year and facing several others in the near future, AstraZeneca has turned in a number of directions to offset potential losses from big sellers like Pulmicort Respules, Nexium, Seroquel, andArimidex, often with mixed results
You may also be interested in...
AZ's emerging markets strategy includes selective entry into branded generics
Innovation-only AstraZeneca gets the branded generics religion, at least in emerging markets.
Facing a raft of patent expiries, AstraZeneca pays richly for Rigel's Phase II oral RA candidate.